Syndax Pharmaceuticals, Inc.
SNDX
$10.91
$0.211.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.04M | 7.68M | 12.50M | 3.50M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.04M | 7.68M | 12.50M | 3.50M | -- |
| Cost of Revenue | 885.00K | 66.36M | 70.97M | 48.66M | -- |
| Gross Profit | 19.16M | -58.68M | -58.47M | -45.16M | -- |
| SG&A Expenses | 41.03M | 37.69M | 31.11M | 29.06M | 23.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.55M | 104.05M | 102.08M | 77.72M | 79.51M |
| Operating Income | -83.51M | -96.37M | -89.58M | -74.22M | -79.51M |
| Income Before Tax | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M |
| EBIT | -83.51M | -96.37M | -89.58M | -74.22M | -79.51M |
| EBITDA | -83.51M | -96.37M | -89.58M | -74.21M | -79.51M |
| EPS Basic | -0.98 | -1.10 | -0.98 | -0.80 | -0.85 |
| Normalized Basic EPS | -0.62 | -0.69 | -0.62 | -0.50 | -0.53 |
| EPS Diluted | -0.98 | -1.10 | -0.98 | -0.80 | -0.85 |
| Normalized Diluted EPS | -0.62 | -0.69 | -0.62 | -0.50 | -0.53 |
| Average Basic Shares Outstanding | 86.17M | 85.79M | 85.43M | 85.27M | 85.21M |
| Average Diluted Shares Outstanding | 86.17M | 85.79M | 85.43M | 85.27M | 85.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |